Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials

Citations Over TimeTop 10% of 2023 papers

Abstract

Breast cancer (BrCa) is the leading cause of cancer incidence and mortality in women worldwide. While BrCa treatment has been shown to be highly successful if detected at an early stage, there are few effective strategies to treat metastatic tumours. Hence, metastasis remains the main cause in most of BrCa deaths, highlighting the need for new approaches in this group of patients. Immunotherapy has been gaining attention as a new treatment for BrCa metastasis and the kynurenine pathway (KP) has been suggested as one of the potential targets. The KP is the major biochemical pathway in tryptophan (TRP) metabolism, catabolising TRP to nicotinamide adenine dinucleotide (NAD+). The KP has been reported to be elevated under inflammatory conditions such as cancers and that its activity suppresses immune surveillance. Dysregulation of the KP has previously been reported implicated in BrCa. This review aims to discuss and provide an update on the current mechanisms involved in KP-mediated immune suppression and cancer growth. Furthermore, we also provide a summary on 58 studies about the involvement of the KP and BrCa and five clinical trials targeting KP enzymes and their outcome.

Related Papers

• → Central kynurenine pathway shift with age in women(2015)94 cited
• → Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia(2018)47 cited
• → The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder(2020)43 cited
• → Stimulatory effect of repeated treatment with lipopolysaccharide on a key enzyme of the kynurenine pathway in both genders in rats(2016)2 cited
• → The role of kynurenine pathway metabolites in the development of frailty in older adults(2023)1 cited